The Role of Umbilical Cord Serum Therapy on Improvement of Corneal Epithelial Defect Following Diabetic Vitrectomy
This trial is active, not recruiting.
|Condition||corneal epithelial defect|
|Treatments||conventional therapy plus umbilical cord serum eye drop, conventional therapy|
|Sponsor||Shahid Beheshti Medical University|
|Collaborator||Ophthalmic Research Center|
|Trial identifier||NCT01168375, 8742|
80 diabetic patients underwent vitrectomy and had no history of Eye herpes infection, Refractive surgery, Autoimmune disease, Immune deficiency will be randomized into two groups (double blind)to evaluate the role of umbilical cord serum therapy on improvement of corneal epithelial defect following diabetic vitrectomy. Both groups will take the conventional medication including Chloramphenicol, Betamethasone, Cycloplegic eye drops besides the case group will take umbilical cord serum eye drop in the eye operated. After surgery the corneal epithelial defect will be measured by slit lamp.
measurement of corneal epithelial defect
Male or female participants of any age.
Inclusion Criteria: - Diabetic patients with corneal epithelial defect following diabetic vitrectomy at labbafinejad Hospital Exclusion Criteria: - Any history of Eye herpes infection, Refractive surgery, Autoimmune disease, Immune deficiency - Patients with one eye - Use of any eye drops except Chloramphenicol, Betamethasone, Cycloplegic and contact lens for corneal epithelial defect
|Official title||The Role of Umbilical Cord Serum Therapy on Improvement of Corneal Epithelial Defect Following Diabetic Vitrectomy|
Call for more information